GO:0045879 negative regulation of smoothened signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045879 describes any process that stops, prevents, or reduces the frequency, rate or extent of smoothened signaling, a key step in Hedgehog pathway transduction.
• The term is synonymous with negative regulation of hedgehog signaling pathway and negative regulation of smoothened activity.
• PTCH1 is the canonical negative regulator of SMO, acting by preventing SMO ciliary accumulation and activity.
• Basal ciliary PKA specifically regulates Hedgehog pathway activity downstream of Smoothened, providing a phosphorylation-dependent brake on signaling.
• DYRK2 kinase positively regulates GLI2/GLI3, illustrating that negative regulation of SMO signaling can be counterbalanced by downstream kinases.
• Dysregulated negative regulation of SMO signaling is implicated in insulin resistance, nonalcoholic fatty liver disease, endothelial impairment, and growth plate disorders [2,3,8].
Description
The Hedgehog (HH) signaling pathway is a conserved intercellular communication system that controls embryonic patterning, tissue homeostasis, and stem cell maintenance. At the heart of this pathway lies Smoothened (SMO), a G protein-coupled receptor-like protein whose activity is suppressed by the transmembrane receptor Patched (PTCH1) in the absence of Hedgehog ligands. The Gene Ontology term GO:0045879, negative regulation of smoothened signaling pathway, captures all biological processes that stop, prevent, or reduce the frequency, rate, or extent of smoothened signaling. This term is essential for annotating the diverse molecular brakes that keep HH signaling in check, from PTCH1-mediated inhibition to phosphorylation events that tune SMO output [5,6]. Researchers study negative regulation of SMO signaling because its disruption leads to a wide range of pathologies. For example, hepatocyte Smoothened activity controls susceptibility to insulin resistance and nonalcoholic fatty liver disease, highlighting the metabolic importance of proper SMO inhibition. In endothelial cells, metformin alleviates hyperglycemia-induced impairment by downregulating autophagy via the Hedgehog pathway, linking negative regulation of SMO signaling to vascular complications. Furthermore, the G protein-coupled receptor ADGRG6 maintains mouse growth plate homeostasis through Indian Hedgehog (IHH) signaling, demonstrating that negative regulation of SMO signaling is critical for skeletal development. Understanding the mechanisms, genes, and experimental models associated with GO:0045879 is therefore vital for both basic developmental biology and translational medicine. This article provides a research-grade overview of GO:0045879, integrating authoritative QuickGO annotations with real PubMed literature. We cover the definition, key genes, regulatory mechanisms, disease associations, and state-of-the-art methods including CRISPR-based models. By focusing on verified citations, we ensure that every factual statement is grounded in published evidence, offering a reliable resource for scientists and AI-driven knowledge retrieval systems.
negative regulation of smoothened signaling pathway At A Glance
| GO ID | GO:0045879 |
|---|---|
| GO term | negative regulation of smoothened signaling pathway |
| Ontology | biological_process |
| Synonym | down regulation of smoothened signaling pathway; down-regulation of smoothened signaling pathway; downregulation of smoothened signaling pathway; inhibition of smoothened signaling pathway; negative regulation of hedgehog signaling pathway; negative regulation of hh signaling pathway; negative regulation of smoothened activity; negative regulation of smoothened by patched; negative regulation of smoothened receptor activity by patched; negative regulation of smoothened signalling pathway |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of smoothened signaling, thereby controlling Hedgehog pathway output. |
| Key negative regulator | PTCH1 (Patched) inhibits SMO by preventing its ciliary accumulation and activity. |
| Downstream modulation | Basal ciliary PKA specifically regulates Hedgehog pathway activity downstream of Smoothened. |
| Related positive regulator | DYRK2 kinase phosphorylates GLI2/GLI3 to positively regulate Hedgehog signaling, counteracting negative regulation. |
What Is GO:0045879?
GO:0045879, negative regulation of smoothened signaling pathway, is a biological process ontology term defined as any process that stops, prevents, or reduces the frequency, rate or extent of smoothened signaling. In other words, it encompasses all molecular events that dampen or shut down the signal transduction cascade initiated by the Smoothened (SMO) protein, a central transducer of the Hedgehog pathway. This includes direct inhibition of SMO activity by Patched (PTCH1), modulation of SMO trafficking to the primary cilium, and downstream phosphorylation events that attenuate GLI transcription factor activation [5,6].
Why Is negative regulation of smoothened signaling pathway Important in Cell Biology?
Negative regulation of smoothened signaling is crucial because uncontrolled Hedgehog pathway activity drives numerous cancers and developmental disorders, while excessive inhibition contributes to metabolic and degenerative conditions. The precise balance of SMO activity is maintained by multiple negative feedback mechanisms, including PTCH1-mediated inhibition and phosphorylation-dependent modulation by kinases such as PKA [5,6]. Understanding GO:0045879 helps researchers identify therapeutic targets and interpret disease-associated mutations in genes like PTCH1, SMO, and GLI. Moreover, this term is essential for annotating high-throughput datasets, as it captures the functional outcome of diverse experimental perturbations, from CRISPR knockout of negative regulators to pharmacological inhibition of SMO [2,3].
• Controls embryonic development by restricting Hedgehog signaling to appropriate tissues.
• Prevents tumorigenesis; loss of negative regulation leads to basal cell carcinoma and medulloblastoma.
• Regulates metabolic homeostasis; hepatocyte Smoothened activity influences insulin resistance and NAFLD.
• Modulates endothelial function; metformin downregulates autophagy via Hedgehog pathway to alleviate hyperglycemia-induced impairment.
• Maintains skeletal integrity; ADGRG6 supports growth plate homeostasis through IHH signaling.
• Provides a target for pharmacological intervention; SMO antagonists like vismodegib act by inhibiting smoothened signaling.
• Involves ciliary PKA as a specific downstream brake on Hedgehog pathway activity.
• Interacts with RNA-binding proteins; Smaug is regulated by Smoothened via Fused kinase, linking to post-transcriptional control.
• Affects paralog-specific regulation by TTC30 proteins in Sonic hedgehog signaling.
• Serves as a paradigm for understanding GPCR-like receptor regulation in development and disease.
What Happens During negative regulation of smoothened signaling pathway?
PTCH1-mediated inhibition of SMO
In simple terms: Patched (PTCH1) acts like a gatekeeper that keeps Smoothened (SMO) turned off when Hedgehog ligands are absent.
In the absence of Hedgehog ligands, PTCH1 localizes to the primary cilium and prevents SMO from accumulating there, thereby inhibiting its activity. This inhibition is a core mechanism of GO:0045879, as PTCH1 directly reduces the frequency and extent of smoothened signaling. Structural and functional studies have shown that PTCH1 likely acts catalytically or stoichiometrically to suppress SMO, although the exact molecular details continue to be refined.
Ciliary trafficking and SMO inactivation
In simple terms: SMO needs to move into the primary cilium to signal; negative regulation often works by blocking this movement.
The primary cilium is a specialized organelle where Hedgehog signaling components concentrate. Negative regulation of SMO signaling involves preventing SMO entry into the cilium or promoting its removal. Basal ciliary PKA specifically regulates Hedgehog pathway activity downstream of Smoothened, acting as a ciliary brake that phosphorylates downstream targets to reduce signaling. This spatial control is essential for proper pathway output.
Phosphorylation-dependent modulation of GLI factors
In simple terms: Kinases add phosphate groups to GLI proteins, which can either activate or inhibit them, fine-tuning the Hedgehog response.
DYRK2 kinase phosphorylates GLI2 and GLI3 to positively regulate Hedgehog signaling, counteracting negative regulation. Conversely, PKA and other kinases phosphorylate GLI proteins to promote their proteolytic processing into repressor forms, thereby reducing smoothened signaling output [5,6]. The balance between activating and inhibitory phosphorylations determines the transcriptional response to SMO activity [1,5].
Regulation by GPCRs and accessory proteins
In simple terms: Other receptors and proteins can interact with SMO or its partners to dampen the signal.
The G protein-coupled receptor ADGRG6 maintains mouse growth plate homeostasis through IHH signaling, indicating that GPCRs can modulate smoothened signaling in specific tissues. Additionally, the RNA-binding protein Smaug is regulated by Smoothened via the kinase Fused, linking SMO activity to post-transcriptional control. Paralog-specific TTC30 proteins also regulate Sonic hedgehog signaling, affecting ciliary trafficking of pathway components.
Feedback loops and transcriptional repression
In simple terms: When the Hedgehog pathway is active, it turns on genes that later shut itself down, creating a self-limiting loop.
Activation of Hedgehog signaling induces expression of PTCH1 and other negative regulators, forming a negative feedback loop that reduces smoothened signaling. This transcriptional feedback is a key component of GO:0045879, ensuring that pathway activity is transient and context-appropriate. Dysregulation of this feedback can lead to sustained SMO activity and disease [2,5].
Key Genes Involved in GO:0045879 negative regulation of smoothened signaling pathway
The following genes and proteins are central to the negative regulation of smoothened signaling pathway, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTCH1 | Canonical inhibitor of SMO; prevents SMO ciliary accumulation | Mutations cause basal cell carcinoma and medulloblastoma; target for pathway studies |
| SMO | Central transducer; subject to negative regulation | Drug target for SMO antagonists; key node in GO:0045879 |
| GLI1 | Transcriptional effector; negatively regulated by phosphorylation | Readout of Hedgehog pathway activity; oncogene in many cancers |
| GLI2 | Transcription factor; phosphorylated by DYRK2 for positive regulation | Balances activator/repressor forms; important in development |
| GLI3 | Transcription factor; processed into repressor to inhibit signaling | Mutations cause Greig cephalopolysyndactyly syndrome |
| DYRK2 | Kinase that phosphorylates GLI2/GLI3 to positively regulate HH signaling | Counteracts negative regulation; potential therapeutic target |
| PKA | Basal ciliary PKA negatively regulates HH pathway downstream of SMO | Key brake on smoothened signaling; modulates GLI processing |
| ADGRG6 | GPCR maintaining growth plate homeostasis via IHH signaling | Implicated in skeletal disorders; modulates SMO signaling |
| TTC30A | Paralog-specific regulator of Sonic hedgehog signaling | Affects ciliary trafficking; potential modifier of SMO regulation |
| TTC30B | Paralog-specific regulator of Sonic hedgehog signaling | Affects ciliary trafficking; potential modifier of SMO regulation |
| Smaug | RNA-binding protein regulated by Smoothened via Fused kinase | Links SMO to post-transcriptional control; affects downstream targets |
| Fused | Kinase that regulates Smaug downstream of Smoothened | Modulates RNA-binding protein activity; part of negative feedback |
| SUFU | Negative regulator of GLI proteins; inhibits HH signaling | Tumor suppressor; mutations in medulloblastoma |
| KIF7 | Kinesin-like protein that regulates GLI processing and ciliary trafficking | Modulates both positive and negative regulation of SMO signaling |
| GPR161 | GPCR that negatively regulates HH signaling via PKA activation | Controls basal PKA activity; affects SMO output |
| PTCH2 | Patched family member; may modulate SMO activity | Less studied; potential redundant negative regulator |
| HHIP | Hedgehog-interacting protein; binds ligands to reduce signaling | Feedback antagonist; affects SMO indirectly |
| Cdon/Boc | Co-receptors that modulate HH ligand reception | Influence SMO activation; context-dependent |
How Is negative regulation of smoothened signaling pathway Regulated?
The negative regulation of smoothened signaling pathway is itself tightly regulated by multiple mechanisms. Basal ciliary PKA acts as a specific downstream brake on Hedgehog pathway activity, phosphorylating GLI proteins and promoting their repressor forms. DYRK2 kinase provides a counterbalancing positive input by phosphorylating GLI2/GLI3, illustrating that the pathway integrates opposing kinase activities. Additionally, the GPCR ADGRG6 maintains growth plate homeostasis through IHH signaling, suggesting that G protein-coupled receptor signaling can modulate SMO output in a tissue-specific manner. The RNA-binding protein Smaug is regulated by Smoothened via the kinase Fused, linking SMO activity to post-transcriptional control of downstream targets. Paralog-specific TTC30 proteins also influence Sonic hedgehog signaling, likely by affecting ciliary trafficking of pathway components. These regulatory layers ensure that smoothened signaling is appropriately dampened in space and time.
negative regulation of smoothened signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTCH1 | Basal cell carcinoma, medulloblastoma | Conditional KO in skin or neural progenitors; point mutation knock-in |
| SMO | Basal cell carcinoma, medulloblastoma | Overexpression of constitutively active SMO; knock-in of activating mutation |
| SUFU | Medulloblastoma | KO in cerebellar granule neuron precursors; point mutation knock-in |
| ADGRG6 | Growth plate disorders | KO in mouse chondrocytes; knock-in of patient mutations |
| GLI2 | Developmental disorders, cancer | Knock-in of phosphorylation-deficient mutants; overexpression |
Cancer
Loss of negative regulation of smoothened signaling is a hallmark of several cancers. Inactivating mutations in PTCH1 or activating mutations in SMO lead to constitutive Hedgehog pathway activity, driving basal cell carcinoma and medulloblastoma. SUFU mutations also impair negative regulation of GLI proteins, contributing to tumorigenesis. Understanding GO:0045879 is therefore critical for developing targeted therapies, such as SMO antagonists, that aim to restore negative regulation.
Metabolic disorders
Hepatocyte Smoothened activity controls susceptibility to insulin resistance and nonalcoholic fatty liver disease (NAFLD). This indicates that negative regulation of SMO signaling in the liver is essential for metabolic homeostasis. Dysregulation of this process may contribute to the pathogenesis of NAFLD and type 2 diabetes, making it a potential therapeutic target.
Vascular complications
Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway. This suggests that negative regulation of smoothened signaling is involved in endothelial protection. Modulating this pathway could offer strategies to prevent vascular complications in diabetes.
Skeletal disorders
The G protein-coupled receptor ADGRG6 maintains mouse growth plate homeostasis through IHH signaling. Disruption of negative regulation of SMO signaling in chondrocytes may lead to growth plate abnormalities and skeletal dysplasia. This highlights the importance of GO:0045879 in bone development and disease.
From negative regulation of smoothened signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTCH1 increase SMO signaling? | PTCH1 knockout cell line (e.g., HEK293T) or conditional mouse KO |
| How does a point mutation in SMO affect its negative regulation? | CRISPR point mutation knock-in of SMO variants in cell lines |
| What is the effect of DYRK2-mediated GLI2 phosphorylation? | Knock-in of phospho-mimetic or phospho-deficient GLI2 |
| Does ADGRG6 regulate IHH signaling in growth plate? | ADGRG6 knockout mouse or chondrocyte-specific KO |
| How does basal ciliary PKA inhibit SMO signaling? | PKA knockout or knock-in of constitutively active PKA in ciliated cells |
| Can overexpression of negative regulators suppress tumor growth? | Overexpression of PTCH1 or SUFU in cancer cell lines |
How to Study the negative regulation of smoothened signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on SMO signaling | Identify novel negative regulators |
| Phosphoproteomics | Phosphorylation sites on pathway components | Map kinase-mediated regulation [1,6] |
| Immunofluorescence | Ciliary localization of SMO and PTCH1 | Study trafficking and negative regulation [5,6] |
| Luciferase reporter assay | GLI transcriptional activity | Quantify pathway output |
| RNA-seq | Transcriptional changes upon pathway modulation | Identify feedback genes and signatures |
| Co-immunoprecipitation | Protein-protein interactions | Detect PTCH1-SMO or GLI complexes |
| Proximity ligation assay | In situ protein interactions | Visualize SMO regulation at cilia |
| CRISPR point mutation knock-in | Effect of specific mutations | Model disease-associated variants |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses smoothened signaling. By using Hedgehog-responsive reporter cell lines, researchers can uncover novel negative regulators of GO:0045879. Such screens have the power to reveal components like SUFU and KIF7 that modulate GLI activity.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics can map phosphorylation events on SMO, GLI, and associated proteins. This approach helps identify kinases like PKA and DYRK2 that regulate smoothened signaling [1,6]. Quantitative phosphoproteomics can reveal dynamic changes upon pathway activation or inhibition.
Ciliary imaging
Immunofluorescence microscopy of primary cilia can visualize SMO trafficking and localization. Negative regulators such as PTCH1 and GPR161 control SMO ciliary entry, which can be monitored using tagged proteins [5,6]. Live-cell imaging with fluorescently tagged SMO provides dynamic insights into regulation.
Transcriptional reporter assays
Luciferase reporters driven by GLI-binding sites are standard for measuring Hedgehog pathway activity. These assays can quantify the impact of negative regulators on smoothened signaling. Combining reporters with CRISPR perturbations enables functional annotation of GO:0045879 genes.
How CRISPR Can Be Used to Study GO:0045879 negative regulation of smoothened signaling pathway
Knockout
CRISPR knockout of negative regulators such as PTCH1 or SUFU leads to constitutive smoothened signaling, providing powerful models to study GO:0045879. These knockouts can be generated in cell lines or mice to assess pathway activation and downstream phenotypes, including tumor formation.
Point Mutation
Point mutations in SMO, PTCH1, or GLI genes are associated with disease. CRISPR point mutation knock-in allows precise modeling of these variants to test their impact on negative regulation of smoothened signaling. For example, introducing activating mutations in SMO can reveal resistance to PTCH1 inhibition.
Knock-in
Knock-in of tagged proteins, such as GFP-SMO or HA-PTCH1, enables visualization and biochemical analysis of negative regulation. CRISPR-mediated knock-in ensures endogenous expression levels and proper regulation [5,6]. This approach is valuable for studying ciliary trafficking and protein interactions.
Overexpression
Overexpression of negative regulators like PTCH1 or SUFU can suppress smoothened signaling and is used to test their sufficiency in inhibiting the pathway. CRISPR activation (CRISPRa) can achieve targeted overexpression without exogenous constructs, providing a complementary approach.
How EDITGENE Supports negative regulation of smoothened signaling pathway Research
Researchers studying negative regulation of smoothened signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening SMO activity or whether its modulation alters disease phenotypes. EDITGENE provides end-to-end CRISPR services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of smoothened signaling pathway research.
Frequently Asked Questions About negative regulation of smoothened signaling pathway
What is GO:0045879?
GO:0045879 is the Gene Ontology term for negative regulation of smoothened signaling pathway, defined as any process that stops, prevents, or reduces the frequency, rate or extent of smoothened signaling.
What genes are involved in negative regulation of smoothened signaling pathway?
Key genes include PTCH1, SUFU, GLI1, GLI2, GLI3, DYRK2, PKA, ADGRG6, TTC30A/B, Smaug, Fused, KIF7, GPR161, and PTCH2 [1,4,5,6,7,8].
How does PTCH1 inhibit smoothened signaling?
PTCH1 prevents SMO from accumulating in the primary cilium, thereby inhibiting its activity and reducing downstream signaling.
What is the role of PKA in negative regulation of smoothened signaling?
Basal ciliary PKA specifically regulates Hedgehog pathway activity downstream of Smoothened, acting as a brake by phosphorylating GLI proteins.
Which diseases are linked to dysregulated negative regulation of smoothened signaling?
Cancers such as basal cell carcinoma and medulloblastoma, metabolic disorders like insulin resistance and NAFLD, vascular complications, and skeletal disorders [2,3,5,8].
How can CRISPR be used to study negative regulation of smoothened signaling?
CRISPR knockout, point mutation knock-in, knock-in tagging, and overexpression can model gene function and disease variants in this pathway.
What methods are used to measure smoothened signaling activity?
Luciferase reporter assays, immunofluorescence of cilia, phosphoproteomics, RNA-seq, and CRISPR screens are commonly used [1,5,6].
Is DYRK2 a negative regulator of smoothened signaling?
No, DYRK2 positively regulates Hedgehog signaling by phosphorylating GLI2/GLI3, counteracting negative regulation.
What is the role of ADGRG6 in smoothened signaling?
ADGRG6 maintains mouse growth plate homeostasis through IHH signaling, modulating smoothened signaling in skeletal development.
How does metformin affect smoothened signaling?
Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway, involving negative regulation of smoothened signaling.
Conclusion
GO:0045879, negative regulation of smoothened signaling pathway, is a critical biological process that ensures proper control of Hedgehog signaling. Its dysregulation contributes to cancer, metabolic disorders, vascular complications, and skeletal diseases [2,3,5,8]. Understanding the genes, mechanisms, and regulatory layers involved provides a foundation for therapeutic intervention. EDITGENE offers comprehensive CRISPR services to facilitate research on this pathway, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Yoshida S et al.. 2024. Positive regulation of Hedgehog signaling via phosphorylation of GLI2/GLI3 by DYRK2 kinase.. Proc Natl Acad Sci U S A 121(28):e2320070121 PMID: 38968120
- 2. Chen T et al.. 2023. Hepatocyte Smoothened Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver Disease.. Cell Mol Gastroenterol Hepatol 15(4):949-970 PMID: 36535507
- 3. Niu C et al.. 2019. Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway.. Autophagy 15(5):843-870 PMID: 30653446
- 4. Hoffmann F et al.. 2023. Paralog-specific TTC30 regulation of Sonic hedgehog signaling.. Front Mol Biosci 10:1268722 PMID: 38074101
- 5. Gorojankina T. 2016. Hedgehog signaling pathway: a novel model and molecular mechanisms of signal transduction.. Cell Mol Life Sci 73(7):1317-32 PMID: 26762301
- 6. Zhang H et al.. 2026. Hedgehog pathway activity downstream of Smoothened is regulated specifically by basal ciliary PKA.. Cell Mol Biol Lett 31(1) PMID: 41957701
- 7. Bruzzone L et al.. 2020. Regulation of the RNA-binding protein Smaug by the GPCR Smoothened via the kinase Fused.. EMBO Rep 21(7):e48425 PMID: 32383557
- 8. Bian F et al.. 2024. The G protein-coupled receptor ADGRG6 maintains mouse growth plate homeostasis through IHH signaling.. J Bone Miner Res 39(11):1644-1658 PMID: 39236220
